Immix Biopharma, Inc.
IMMX
$2.03
-$0.065-3.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 22.49% | 19.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -32.56% | 57.25% | |||
| Operating Income | 32.56% | -57.25% | |||
| Income Before Tax | 32.74% | -62.40% | |||
| Income Tax Expenses | -2.70% | 7.77% | |||
| Earnings from Continuing Operations | 32.69% | -62.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 32.69% | -62.75% | |||
| EBIT | 32.56% | -57.25% | |||
| EBITDA | 32.79% | -57.27% | |||
| EPS Basic | 33.00% | -59.24% | |||
| Normalized Basic EPS | 33.05% | -59.58% | |||
| EPS Diluted | 33.00% | -59.24% | |||
| Normalized Diluted EPS | 33.05% | -59.58% | |||
| Average Basic Shares Outstanding | 0.47% | 2.22% | |||
| Average Diluted Shares Outstanding | 0.47% | 2.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||